View Ray, Inc. VRAY
We take great care to ensure that the data presented and summarized in this overview for ViewRay, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VRAY
View all-
Parian Global Management LP Pound Ridge, NY265KShares$2,6503.14% of portfolio
-
Telemetry Investments, L.L.C. New York, NY200KShares$2,0001.42% of portfolio
-
Jefferies Group LLC New York, NY169KShares$1,6910.01% of portfolio
-
Rovin Capital20KShares$2000.0% of portfolio
-
Boston Family Office LLC Boston, MA10KShares$1000.0% of portfolio
-
Wipfli Financial Advisors Llc,362Shares$30.0% of portfolio
Latest Institutional Activity in VRAY
Top Purchases
Top Sells
About VRAY
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
Insider Transactions at VRAY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 21
2023
|
Sanket Shah SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
30,364
-7.29%
|
$0
$0.08 P/Share
|
|
Jul 21
2023
|
B Kristine Johnson Director |
SELL
Open market or private sale
|
Direct |
30,702
-19.5%
|
$0
$0.05 P/Share
|
|
Jul 21
2023
|
Karen Prange Director |
SELL
Open market or private sale
|
Direct |
37,600
-81.04%
|
$0
$0.05 P/Share
|
|
Jul 20
2023
|
Farhad Fred Ebrahimi |
SELL
Open market or private sale
|
Indirect |
8,203,610
-66.39%
|
$0
$0.06 P/Share
|
|
Jul 19
2023
|
Farhad Fred Ebrahimi |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
453,600
+3.3%
|
$907,200
$2.63 P/Share
|
|
Jul 19
2023
|
Karen Prange Director |
SELL
Open market or private sale
|
Direct |
91,866
-66.44%
|
$0
$0.08 P/Share
|
|
Jul 19
2023
|
Paul Ziegler Jr Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
169,785
-10.65%
|
$0
$0.07 P/Share
|
|
Jul 19
2023
|
Caley Castelein Director |
SELL
Open market or private sale
|
Indirect |
1,545,600
-100.0%
|
$0
$0.07 P/Share
|
|
Jul 19
2023
|
Caley Castelein Director |
SELL
Open market or private sale
|
Direct |
799,430
-52.12%
|
$0
$0.07 P/Share
|
|
Jul 18
2023
|
Farhad Fred Ebrahimi |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
49,800
+0.72%
|
$49,800
$1.5 P/Share
|
|
Jul 18
2023
|
Scott William Drake Director |
SELL
Open market or private sale
|
Direct |
2,408,747
-60.21%
|
$0
$0.06 P/Share
|
|
Jul 18
2023
|
B Kristine Johnson Director |
SELL
Open market or private sale
|
Direct |
79,622
-33.59%
|
$0
$0.07 P/Share
|
|
Jul 17
2023
|
Adam Andrew Podbelski SVP, Customer Services |
SELL
Open market or private sale
|
Direct |
89,901
-16.74%
|
$0
$0.07 P/Share
|
|
Jul 17
2023
|
Farhad Fred Ebrahimi |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
496,300
+2.84%
|
$496,300
$1.5 P/Share
|
|
Jul 15
2023
|
Adam Andrew Podbelski SVP, Customer Services |
BUY
Grant, award, or other acquisition
|
Direct |
350,000
+39.46%
|
-
|
|
Jul 15
2023
|
Sanket Shah SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
350,000
+45.65%
|
-
|
|
Jul 15
2023
|
Paul Ziegler Jr Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,200,000
+42.96%
|
-
|
|
Jul 05
2023
|
Farhad Fred Ebrahimi |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
13,600
+0.17%
|
$13,600
$1.5 P/Share
|
|
Jun 28
2023
|
Farhad Fred Ebrahimi |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
236,100
+1.81%
|
$708,300
$3.8 P/Share
|
|
Jun 15
2023
|
Scott William Drake Director |
SELL
Payment of exercise price or tax liability
|
Direct |
116,003
-2.82%
|
$0
$0.48 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.9M shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 1.25M shares |
| Open market or private sale | 13.5M shares |
|---|---|
| Payment of exercise price or tax liability | 125K shares |